New drug combo aims to stop liver cancer recurrence in transplant patients

NCT ID NCT02081755

ENROLLING_BY_INVITATION Disease control Sponsor: Baylor Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug everolimus can lower the risk of liver cancer coming back after a liver transplant in patients with high-risk hepatocellular carcinoma. About 336 adults who have just received a transplant will be randomly assigned to take everolimus plus tacrolimus or standard immunosuppressants. The main goal is to see how long patients live without their cancer returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Everolimus (also known as Zortress or Afinitor)
What this could lead to: If successful, this could point toward a way to lower the chance of liver cancer coming back after a transplant, helping patients live longer without recurrence.
What could go wrong: This is a phase 4 study, so the drug is already approved, but it's still uncertain if everolimus will outperform standard treatments. Risks include side effects like infections, kidney problems, and wound healing issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Locations

Baylor University Medical Center

Dallas, Texas, 75246, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mount Sinai Medical Center

New York, New York, 10029, United States
Northwestern University School of Medicine

Chicago, Illinois, 60611, United States
University of California at San Francisco

San Francisco, California, 94143, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Tennessee- Methodist University Hospital

Memphis, Tennessee, 38104, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.